Altimmune Stock Retained Earnings
| ALT Stock | USD 8.25 0.07 0.86% |
Altimmune fundamentals help investors to digest information that contributes to Altimmune's financial success or failures. It also enables traders to predict the movement of Altimmune Stock. The fundamental analysis module provides a way to measure Altimmune's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Altimmune stock.
| Last Reported | Projected for Next Year | ||
| Retained Earnings | -466.3 M | -443 M | |
| Retained Earnings Total Equity | -337.1 M | -354 M |
Altimmune | Retained Earnings |
Altimmune Company Retained Earnings Analysis
Altimmune's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Altimmune Retained Earnings | (466.33 M) |
Most of Altimmune's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Altimmune is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Altimmune Retained Earnings Driver Correlations
Understanding the fundamental principles of building solid financial models for Altimmune is extremely important. It helps to project a fair market value of Altimmune Stock properly, considering its historical fundamentals such as Retained Earnings. Since Altimmune's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Altimmune's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Altimmune's interrelated accounts and indicators.
Click cells to compare fundamentals
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
Based on the latest financial disclosure, Altimmune has a Retained Earnings of (466.33 Million). This is 150.07% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The retained earnings for all United States stocks is 105.0% higher than that of the company.
Altimmune Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Altimmune's direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Altimmune could also be used in its relative valuation, which is a method of valuing Altimmune by comparing valuation metrics of similar companies.Altimmune is currently under evaluation in retained earnings category among its peers.
Altimmune Current Valuation Drivers
We derive many important indicators used in calculating different scores of Altimmune from analyzing Altimmune's financial statements. These drivers represent accounts that assess Altimmune's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Altimmune's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 24.8M | 289.2M | 378.2M | 771.9M | 599.0M | 629.0M | |
| Enterprise Value | 17.6M | 175.1M | 189.4M | 662.0M | 464.6M | 487.8M |
Altimmune ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Altimmune's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Altimmune's managers, analysts, and investors.Environmental | Governance | Social |
Fund Asset Allocation for Altimmune
The fund invests 21.57% of asset under management in tradable equity instruments, with the rest of investments concentrated in bonds (15.26%) and various exotic instruments.Asset allocation divides Altimmune's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
Altimmune Fundamentals
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | 450.24 M | ||||
| Shares Outstanding | 71.12 M | ||||
| Shares Owned By Insiders | 0.79 % | ||||
| Shares Owned By Institutions | 56.67 % | ||||
| Number Of Shares Shorted | 23.43 M | ||||
| Price To Earning | (1.66) X | ||||
| Price To Book | 4.41 X | ||||
| Price To Sales | 11,284 X | ||||
| Revenue | 426 K | ||||
| Gross Profit | (70.52 M) | ||||
| EBITDA | (87.94 M) | ||||
| Net Income | (88.45 M) | ||||
| Cash And Equivalents | 184.76 M | ||||
| Cash Per Share | 3.81 X | ||||
| Total Debt | 671 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 14.12 X | ||||
| Book Value Per Share | 1.88 X | ||||
| Cash Flow From Operations | (75.81 M) | ||||
| Short Ratio | 5.81 X | ||||
| Earnings Per Share | (1.57) X | ||||
| Target Price | 22.86 | ||||
| Number Of Employees | 59 | ||||
| Beta | 0.072 | ||||
| Market Capitalization | 586.78 M | ||||
| Total Asset | 210.64 M | ||||
| Retained Earnings | (466.33 M) | ||||
| Working Capital | 197.48 M | ||||
| Current Asset | 13.9 M | ||||
| Current Liabilities | 10.49 M | ||||
| Year To Date Return | 1.67 % | ||||
| One Year Return | (6.49) % | ||||
| Three Year Return | (0.57) % | ||||
| Net Asset | 210.64 M | ||||
| Equity Positions Weight | 21.57 % | ||||
| Bond Positions Weight | 15.26 % |
About Altimmune Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Altimmune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Altimmune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Altimmune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Altimmune Stock Analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.